Comparação de isolados de Herpesvírus bovino tipo 5 (BoHV-5) como candidatos à vacina

• Ano de defesa: 2006
• Autor(a) principal: Souza, Luiz Felipe Lourenço de
• Orientador(a): Moraes, Mauro Pires
• Banca de defesa: Moreira, Maria Aparecida Scatamburlo , Pinto, Paulo Sérgio de Arruda , Paula, Sérgio Oliveira de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Viçosa
• Programa de Pós-Graduação: Mestrado em Medicina Veterinária
• Departamento: Biotecnologia, diagnóstico e controle de doenças; Epidemiologia e controle de qualidade de prod. de
• País: BR
• Palavras-chave em Português: Herpesvírus bovino; BoHV-5; Meningoencefalite bovina; Vacina inativada; Soroneutralização
• Palavras-chave em Inglês: Bovine herpesvirus; BoHV-5; Bovine meningoencephalitis; Vaccine; Virus-neutralization
• Área do conhecimento CNPq: CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::MEDICINA VETERINARIA PREVENTIVA
• Link de acesso: http://locus.ufv.br/handle/123456789/5080

Bovine herpesvirus type 5 (BoHV-5) is the etiological agent of the bovine meningoencephalitis that presents high morbidity in young bovine. Due to the similarity in the morphology of the virion, cytopathic effect in cell culture and antigenic properties, the BoHV-5 was classified erroneously as BoHV-1 in the past. BoHV-1 is responsible for respiratory and genital diseases, however the disease caused by BoHV-5 presents neurological clinical signs. This virus has been considered a variant of the same agent (BoHV-1) with neuropathogenic characteristics. Comparative studies among isolates of BoHV-5 revealed 97% of proteic similarity. However, the amino-terminal region of the most abundant glycoprotein of the viral envelope, the gC, differs substantially. This glycoprotein is involved in the initial interactions of the virus with the cellular surface besides of presenting as target for antibodies with neutralizing activities. This study aimed at to select an isolate of BoHV-5, among 5 isolates collected in outbreaks in different properties in Brazil, presenting higher antigenicity in vaccinated animals. Vaccines were formulated using isolates ISO9898292, SV507, SV163, 1807 and EVI145 and administered to 5 groups of 10 sheeps, which have received two intramuscular doses on days 0 and 21. Collections of blood were accomplished for analysis of production of antibodies by virus-neutralization and attendance of possible clinical signs to the 63rd day after the first vaccination. Antibodies titers averages ranged from 6,85 and 14,92 on the day 0 before the first vaccination. Antibody peak were on day 14, ranged from 4,50 (isolated ISO9898292) to 138,63 (isolated SV163). A second peak was observed 14 days after the booster ranged from 7,77 (ISO9898292) to 1017,54 (1807). In the 42nd day after the booster, it was observed titers variation from 3,84 (ISO9898292) to 305,97 (1807). The discrepancy among titers of antibody of each group of animals suggests a smaller antigenicity of isolated ISO9898292 in relation to the others, demonstrating a possible variation among the isolates, what results in antigenic differences. All isolates, with exception to ISO9898292, were effective in the induction of antibodies.